Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study
新辅助disitamab vedotin (RC48-ADC)联合免疫疗法治疗肌层浸润性膀胱癌患者的疗效和生物标志物分析：一项多中心真实世界研究
期刊:Imeta
影响因子:33.2
doi:10.1002/imt2.70033
Hu, Jiao; Yan, Luzhe; Liu, Jinhui; Chen, Minfeng; Liu, Peihua; Deng, Dingshan; Zhang, Chaobin; He, Yunbo; Fan, Benyi; Li, Huihuang; Gong, Guanghui; Xiao, Jiatong; Wang, Ruizhe; Guan, Xiao; Tong, Shiyu; Li, Yangle; Li, Nannan; Tang, Zhiwang; Zhang, Teng; Li, Hao; Huang, Bin; Gao, Ning; He, Wei; Cai, Zhiyong; Liu, Yifan; Liu, Zefu; Gan, Yu; Cui, Yu; Dai, Yuanqing; Cai, Yi; Nie, Zhenyu; Ou, Zhenyu; Chen, Jinbo; Zu, Xiongbing
